tetano
Editor, Senior Moderator
J Fungi (Basel)
. 2021 Dec 31;8(1):44.
doi: 10.3390/jof8010044.
Dental and Oral Manifestations of COVID-19 Related Mucormycosis: Diagnoses, Management Strategies and Outcomes
Omer Sefvan Janjua[SUP] 1 [/SUP], Muhammad Saad Shaikh[SUP] 2 [/SUP], Muhammad Amber Fareed[SUP] 3 [/SUP], Sana Mehmood Qureshi[SUP] 4 [/SUP], Muhammad Ikram Khan[SUP] 5 [/SUP], Danya Hashem[SUP] 6 [/SUP], Muhammad Sohail Zafar[SUP] 6 7 [/SUP]
Affiliations
Abstract
It has been nearly two years since the pandemic caused by the novel coronavirus disease (COVID-19) has affected the world. Several innovations and discoveries related to COVID-19 are surfacing every day and new problems associated with the COVID-19 virus are also coming to light. A similar situation is with the emergence of deep invasive fungal infections associated with severe acute respiratory syndrome 2 (SARS-CoV-2). Recent literature reported the cases of pulmonary and rhino-cerebral fungal infections appearing in patients previously infected by COVID-19. Histopathological analysis of these cases has shown that most of such infections are diagnosed as mucormycosis or aspergillosis. Rhino-orbital-cerebral mucormycosis usually affects the maxillary sinus with involvement of maxillary teeth, orbits, and ethmoidal sinuses. Diabetes mellitus is an independent risk factor for both COVID-19 as well as mucormycosis. At this point, there is scanty data on the subject and most of the published literature comprises of either case reports or case series with no long-term data available. The aim of this review paper is to present the characteristics of COVID-19 related mucormycosis and associated clinical features, outcome, diagnostic and management strategies. A prompt diagnosis and aggressive treatment planning can surely benefit these patients.
Keywords: SARS-CoV-2; aspergillosis; fungal infection; mucormycosis; oral mucormycosis.
. 2021 Dec 31;8(1):44.
doi: 10.3390/jof8010044.
Dental and Oral Manifestations of COVID-19 Related Mucormycosis: Diagnoses, Management Strategies and Outcomes
Omer Sefvan Janjua[SUP] 1 [/SUP], Muhammad Saad Shaikh[SUP] 2 [/SUP], Muhammad Amber Fareed[SUP] 3 [/SUP], Sana Mehmood Qureshi[SUP] 4 [/SUP], Muhammad Ikram Khan[SUP] 5 [/SUP], Danya Hashem[SUP] 6 [/SUP], Muhammad Sohail Zafar[SUP] 6 7 [/SUP]
Affiliations
- PMID: 35049983
- DOI: 10.3390/jof8010044
Abstract
It has been nearly two years since the pandemic caused by the novel coronavirus disease (COVID-19) has affected the world. Several innovations and discoveries related to COVID-19 are surfacing every day and new problems associated with the COVID-19 virus are also coming to light. A similar situation is with the emergence of deep invasive fungal infections associated with severe acute respiratory syndrome 2 (SARS-CoV-2). Recent literature reported the cases of pulmonary and rhino-cerebral fungal infections appearing in patients previously infected by COVID-19. Histopathological analysis of these cases has shown that most of such infections are diagnosed as mucormycosis or aspergillosis. Rhino-orbital-cerebral mucormycosis usually affects the maxillary sinus with involvement of maxillary teeth, orbits, and ethmoidal sinuses. Diabetes mellitus is an independent risk factor for both COVID-19 as well as mucormycosis. At this point, there is scanty data on the subject and most of the published literature comprises of either case reports or case series with no long-term data available. The aim of this review paper is to present the characteristics of COVID-19 related mucormycosis and associated clinical features, outcome, diagnostic and management strategies. A prompt diagnosis and aggressive treatment planning can surely benefit these patients.
Keywords: SARS-CoV-2; aspergillosis; fungal infection; mucormycosis; oral mucormycosis.